Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100331 | 1.00 | HTR2A (0.51) | HTR2AHTR2CHTR2BSLC6A4HTR1A | |
| SCHEMBL4098671 | 0.90 | SLC6A4 (0.50) | HTR2ASLC6A4SLC6A2SLC6A3IDO1 | |
| SCHEMBL4098677 | 0.90 | SLC6A4 (0.50) | HTR2ASLC6A4SLC6A2SLC6A3IDO1 | |
| SCHEMBL13620096 | 0.87 | HTR2A (0.48) | HTR2AHTR2CHTR2BSLC6A4HTR1A | |
| SCHEMBL13620081 | 0.86 | IDO1 (0.50) | SLC6A4SLC6A2SLC6A3IDO1CYP2C19 | |
| SCHEMBL4103244 | 0.86 | HTR2A (0.47) | HTR2AHTR2CHTR2BSLC6A4HTR1A | |
| SCHEMBL4103239 | 0.86 | HTR2A (0.47) | HTR2AHTR2CHTR2BSLC6A4HTR1A | |
| SCHEMBL3978475 | 0.85 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3IDO1CYP2C19 | |
| SCHEMBL4085374 | 0.84 | HTR2C (0.49) | HTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL4097300 | 0.84 | HTR2C (0.49) | HTR2AHTR2CHTR2BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| WO-2009106559-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| CN-101472890-A | 3- (1H-indol- 3-ydindan-1-ylamine derivatives for the treatment of depression and anxiety | LUNDBECK & CO AS H (DK) | 2009-07-01 | — | — | CN | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | OPRL1, HTR2C, SLC6A3 | HTR2A 15/4885HTR2C 2/4885HTR2B 36/4885 |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | GPR119, INSR, IRS1 | HTR2A 103/4885HTR2C 76/4885HTR2B 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.